NAMSA announced today its acquisition of CRI, a German-based full service CRO providing the European MedTech market with complete clinical research solutions to accelerate scientific outcomes to clients.
NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and Terumo Aortic, a developer of aorta-focused medical devices, announced that they have entered into a strategic outsourcing partnership to assist with the acceleration and commercialization of Terumo Aortic’s innovative aortic disease products.
NAMSA announced today its acquisition of SUAZIO, an EU-based strategic consultancy providing global market research services to medical device and IVD developers.
NAMSA announced today the transformation of its integrated MedTech commercialization solution: the NAMSA APEX Program. NAMSA’s strategic outsourcing solution is introduced at a time when the MedTech industry is experiencing changing regulatory requirements and expanding clinical evidence demands
NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today its acquisition of Perfectus Biomed Group, a UK-based laboratory providing customized microbiological services.